Clinical trials: Benign Hyperplasia of Prostate
Erectile Dysfunction
Will Erectile Dysfunction Increase the Risk of Prostate Cancer
The rationale for investigating the hypothesis that there is an association between erectile dysfunction (ED) and the subsequent development of prostate cancer is based on three assumptions: 1) baseline ED is common in most if…
- Trial name
- EDtoPC (NCT03009123)
- Testing
- Erectile dysfunction
- Where
- Taiwan
- Volunteers
- 21,558 people
- Sponsor
- Kuang Tien General Hospital
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Retrospective Review a Comprehensive Case Database of HoLEP Procedure Performed by a Single Surgeon
Persistent detrusor overactivity (DO) after transurethral prostatectomy results in symptomatic failure in more than one third of the patients.
- Trial name
- NCT01604148
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Samsung Medical Center
Benign Prostatic Hyperplasia (BPH), Obstructive Lower Urinary Tract Symptoms (LUTS)
Prospective Post Market Clinical Trial for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH.
This is a prospective, randomized, open-label, parallel-group post-market clinical trial (PMCT). The overall objective of this PMCT is to compare the effectiveness, durability, and patient-centered outcomes of the Zenflow Spring…
- Conditions
- Benign Prostatic Hyperplasia (BPH), Obstructive Lower Urinary Tract Symptoms (LUTS), Enlarged Prostate
- Trial name
- NCT07797348
- Testing
- Zenflow Arm: Zenflow Spring System implant procedure, Medical Therapy Tamsulosin
- Volunteers
- 110 people
- Sponsor
- Zenflow, Inc.
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial
The goal of this randomized crossover clinical trial is to compare the efficacy and safety of Silodosin versus Tamsulosin in patients with moderate to severe lower urinary tract symptoms due to Benign Prostatic Hyperplasia.
- Trial name
- NCT07467343
- Testing
- Silodosin, Tamsulosin
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Ain Shams University
Benign Prostatic Hyperplasia
The Zenflow Spring System EU Safety and Performance Study
The objectives of the trial are to demonstrate the safety and performance of the Zenflow Spring System in relieving the symptoms of obstructive Benign Prostatic Hyperplasia (BPH).
- Trial name
- ZEST EU (NCT03577236)
- Testing
- Zenflow Spring System
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 50 people
- Sponsor
- Zenflow, Inc.
Hyperplasia Prostatic, Lower Urinary Tract Symptoms
Prostatic Artery Embolization for Benign Prostatic Obstruction
The aim of this study is to investigate the safety and efficacy of prostatic artery embolization (PAE) for patients who refuse or are not eligible for surgery with moderate-severe lower urinary tract symptoms or indwelling…
- Conditions
- Hyperplasia Prostatic, Lower Urinary Tract Symptoms, Prostatic Diseases, Urological Manifestations
- Trial name
- NCT03099421
- Testing
- Prostatic Artery Embolization
- Where
- Denmark
- Volunteers
- 11 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Prostatic Hyperplasia
Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia
The primary objective of the study is to demonstrate the superiority of SL77.0499-10 10mg once daily over placebo and the non-inferiority versus tamsulosin hydrochloride after 12 weeks treatment in terms of the efficacy in…
- Trial name
- NCT00399464
- Testing
- alfuzosin
- Where
- Japan
- Volunteers
- 1,177 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia (BPH)
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Inflammation is reported as one of the most recent hypotheses to explain BPH. Recent published works pointed out that urine and serum markers could be used for detection of prostatic inflammation.
- Trial name
- PERMIN (NCT01604811)
- Testing
- Permixon® 160 mg, Tamsulosine Arrow LP
- Where
- 32 sites in France, Italy and 2 more
- Volunteers
- 206 people
- Sponsor
- Pierre Fabre Medicament
Benign Prostatic Hyperplasia
Economic Evaluation of Prostatic Urethral Lift
Prostatic urethral lift (Urolift) has been developed as a minimally invasive alternative to transurethral resection of the prostate with no need of general anaesthesia, less need of urinary catheter and less exposure to…
- Trial name
- ECOLIFT (NCT04726748)
- Testing
- Comparisons between the Prostatic urethral lift (PUL) and the TURP/Laser cohorts, Comparison between the Prostatic urethral lift (PUL) and the SNDS cohorts
- Where
- 6 sites in France
- Volunteers
- 1,360 people
- Sponsor
- University Hospital, Bordeaux
Metabolic Syndrome
Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome
Type 2 diabetes mellitus, insulin resistance, visceral obesity and disorders of lipid metabolism, especially triglyceride and hypertension are metabolic disorders that play a central role in pathophysiology of metabolic syndrome…
- Trial name
- NCT02778776
- Testing
- Metformin, Agave inulin
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Centro Universitario de Ciencias de la Salud, Mexico
Prostatic Hyperplasia
ALF-ONE : ALFuzosin ONcE Daily
The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms…
- Trial name
- NCT00280605
- Testing
- Alfuzosin
- Volunteers
- 200 people
- Sponsor
- Sanofi
Calculi, Renal, Calculi, Urinary
Modified SOLTIVE Study
This is a study to collect procedural data during the use of the SOLTIVE™ Premium SuperPulsed Laser System in the treatment of bladder, ureteral, and kidney stones and BPH to inform the development of software algorithms.
- Conditions
- Calculi, Renal, Calculi, Urinary, Benign Prostatic Hyperplasia
- Trial name
- NCT07838077
- Testing
- SOLTIVE Premium SuperPulsed Laser System
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Olympus Corporation of the Americas
Benign Prostatic Hyperplasia (BPH)
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM System and TURP for the treatment of Lower Urinary Tract Symptoms (LUTS).
- Trial name
- WATER (NCT02505919)
- Testing
- AQUABEAM System, Transurethral Resection of the Prostate (TURP)
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 184 people
- Sponsor
- PROCEPT BioRobotics
Urinary Frequency, Urinary Urgency
Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)
The purpose of this study is to demonstrate that solifenacin post-operatively improves irritative symptoms in men whose obstructive symptoms have been relieved with the GreenLight laser outpatient procedure.
- Conditions
- Urinary Frequency, Urinary Urgency, Nocturia
- Trial name
- NCT00826527
- Testing
- Solifenacin PO
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Seattle Urology Research Center
Benign Prostatic Hyperplasia
Ceasing Alpha-blockers Early After Resection of the Prostate (The CLEAR Trial)
After surgery for benign prostatic hyperplasia (BPH) that physically removes the prostatic transition zone (such as TURP or laser enucleation), many men are routinely sent home with a 2- to 4-week prescription of an alpha-blocker…
- Trial name
- CLEAR (NCT07846579)
- Testing
- Tamsulosin hydrochloride 0.2 mg
- Volunteers
- 400 people
- Sponsor
- Shanghai East Hospital
Prostatic Hyperplasia
One-year Results After Single-center Water Vapor Thermal Therapy for Symptomatic Benign Prostatic Hyperplasia.
Objective: Rezūm vapor ablation is a minimally invasive treatment for benign prostatic hyperplasia (BPH) that uses injections of sterile water vapor directly into the prostate for tissue ablation.
- Trial name
- NCT06257654
- Testing
- REZUM
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Hisar Intercontinental Hospital
Benign Prostatic Hyperplasia (BPH)
Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate
Prognostic factor in the patients with benign prostatic hyperplasia (BPH) who undergo holmium laser enucleation of the prostate
- Trial name
- NCT03460873
- Testing
- holmium laser enucleation of the prostate
- Where
- South Korea
- Volunteers
- 432 people
- Sponsor
- Samsung Medical Center
Benign Prostatic Hyperplasia (BPH)
REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men
The study objective is to compare water vapor thermotherapy with the REZŪM™ System to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia refractory to alpha-blocker monotherapy in sexually active men.
- Trial name
- VAPEUR (NCT04838769)
- Testing
- REZŪM, alpha blocker and 5-alpha reductase inhibitor
- Where
- 21 sites in Australia, France
- Volunteers
- 155 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)
This clinical study is designed to evaluate the efficacy and safety of silodosin in a 12 week treatment of patients with severe urinary disorders associated with benign prostatic hyperplasia (BPH).
- Trial name
- STRONG (NCT01259531)
- Testing
- Silodosin
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- JW Pharmaceutical
Benign Prostatic Hyperplasia
The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia
Non-steroidal Anti-inflammation Drugs can effectively reduce the lower urinary tract symptoms from benign prostatic hyperplasia
- Trial name
- NCT00687388
- Testing
- selective alpha 1-blockers, celecoxib, alpha-blocker and NSAID
- Where
- 3 sites in South Korea
- Sponsor
- Samsung Medical Center